SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a mix of earnings results and news of Michael Burry's significant short position against the stock, sparking debates about valuation and future growth potential. Community discussions revolve around whether the company is overvalued, with some defending its AI capabilities and government contracts, while others point to its high P/E ratio and the potential impact of Burry's bet.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is seeing increased discussion around a potential market correction, with community members pointing to AI overvaluation and heavy leveraging as potential catalysts for a significant pullback. Traders are actively debating whether this dip is a buying opportunity or the start of a longer-term bearish trend, as they watch key support levels. The conversation also includes concerns about political and economic factors influencing market direction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about its recent earnings and the impact of COVID-era data on trial results for PMO therapies; while some express concern over missed statistical significance, others highlight the revenue beat and potential for Elevidys to replace older treatments. The community is debating the likelihood of FDA action on PMO drugs and the company's overall valuation in light of recent events, with some suggesting a buyout opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending amid mixed sentiment heading into earnings, with discussions around a potential deal with Novo Nordisk for weight-loss drugs like Wegovy. The community is closely watching subscriber growth and margin expansion, while analysts debate the impact of increased competition and past concerns regarding GLP-1s. Some traders are betting on a post-earnings squeeze, while others point to technical indicators suggesting further downside.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending amid community discussion around its recent price movements and potential. Some traders highlight its relative strength as Bitcoin and other cryptos decline, while others remain skeptical, citing its past performance. Discussions include its technology, future potential, and the impact of upcoming announcements.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as traders discuss its potential as 'the better Bitcoin' due to its privacy features and limited supply, with some community members speculating about a short squeeze and a rapid price surge to $1,000.  The conversation also highlights ZEC as a hedge against Bitcoin's volatility, with some suggesting a rotation from BTC into ZEC.  Mentions of its upcoming anniversary and bullish technical indicators add to the current hype.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a post-earnings selloff, with the community debating whether the drop is an overreaction or a sign of deeper issues related to AI spending and future profitability. Sentiment is mixed, ranging from calls to buy the dip to concerns about technicals and potential further declines. Some traders are pointing to historical patterns and oversold conditions as potential catalysts for a bounce.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction, trending as a top crypto, with community members highlighting staking options and a strong, active team. Bullish sentiment is fueled by the project's IRL events, pro athlete sponsorships, and consistent presence on multiple platforms. Discussions also revolve around the supportive community and the potential for significant growth.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market navigates a mixed sentiment driven by AI optimism versus concerns about valuations and economic uncertainty. Community members are actively discussing potential overextension in tech, particularly regarding names like NVDA and PLTR, while also monitoring signals for a possible market correction. News regarding potential impacts from the government shutdown and developments in U.S.-China trade relations are adding to the complex market outlook.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab ($GRAB) is trending due to increased retail investor buzz after the company raised its earnings forecast.  The community is discussing its impressive On-Demand GMV growth and raised full-year revenue guidance.  Some see Grab as an emerging fintech opportunity and a dominant player in the Southeast Asian market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.</li><li>The company’s late-stage HOPE-3 trial for Deramiocel remains on track, with topline data expected later this quarter and plans to resubmit its biologics license application afterward.</li><li>Retail traders on Stocktwits voiced optimism that Deramiocel could become the next breakthrough for patients after Sarepta’s setback.</li></ul>Retail chatter around Capricor Therapeutics spiked on Monday after the biotech company published a peer-reviewed study in Biomedicines detailing the mechanism of action and potency assay for its investigational cell therapy, Deramiocel, which is being developed to treat Duchenne muscular dystrophy (DMD).<h2 class="st-heading-2">Peer-Reviewed Study Highlights</h2>The new publication described how Deramiocel’s active components, which are cardiosphere-derived cells (CDCs), suppress fibrosis-related genes such as collagen I and III in human fibroblasts. This anti-fibrotic mechanism supports the therapy’s potential to slow disease progression in DMD.The analysis validated the reliability of a potency&nbsp;test&nbsp;used to demonstrate batch-to-batch consistency of the product. Capricor said the data is in line with more than four years of clinical data showing the cardiac condition has stabilized in patients.<h2 class="st-heading-2">Late-Stage Progress</h2>Capricor CEO Linda Marban said the new assay strengthens confidence in Deramiocel’s biological profile and the company’s ability to ensure consistent quality as it moves deeper into late-stage trials.Deramiocel is in development in the Phase 3 HOPE-3 trial, with data topline anticipated in the middle of the fourth quarter. The company will resubmit the biologics license application (BLA) to the FDA after the data are available.<h2 class="st-heading-2">Stocktwits Traders See Capricor As The Next Hope For DMD Patients</h2>On Stocktwits, retail sentiment for Capricor was ‘extremely bullish’ amid a 565% surge in 24-hour message volume.One user said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-crashes-after-hours-on-dmd-trial-failure-q3-print/cL2FDdvR3Ce">Sarepta’s trial setback</a> was unfortunate for Duchenne muscular dystrophy patients, adding that “these kids deserve better” and that meaningful progress will only come once the FDA approves Capricor’s therapy.&nbsp;<stembedurl>https://stocktwits.com/Pennyforyourbuck/message/634795350</stembedurl>Another user wrote that Capricor now stands as “the last DMD company alive,” predicting that its Phase 3 trial will be “epic” and could send the stock soaring.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/634792751</stembedurl><a href="https://stocktwits.com/symbol/CAPR">Capricor’s stock</a> has declined 56% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.

Equity

Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 28, 2025...

Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains?

Capricor (CAPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR Capricor Therapeutics, Inc. Sued for Securities Law Violations...

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR Faruqi & Faruqi Reminds Capricor Investors of the Pending...

Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates

Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc